Cardiovascular complications during the cancer treatment are one of the reasons of early disability and death of patients as well as caused by tumor recurrence. In this regard, the effectiveness of infusion therapy of meglumine sodium succinate (reamberin) in 160 women with histologically verified locally advanced breast cancer who received 4 courses of anthracycline-containing polychemotherapy has been assessed. After randomization, the patients of the first group (observation group, n=80) received infusion therapy with reamberin at an average daily dose of 10 ml/kg during the first 5 days of each course of chemotherapy; Patients of the second group (comparison group, n=80) received 400 ml of 0.9% sodium chloride solution as a placebo infusion therapy. The reamberin infusion therapy allowed to reduce cardiovascular toxicity during 4 courses of polychemotherapy: the frequency of complaints of heart pain was 26.3—21.3% in the observation group vs 50.0—73.8% in comparison group (p<0.001); the development of sinus tachycardia — 23.8—35% vs 41.3—48.8%, respectively (p<0.05); reduction of ejection fraction — 65.7—62.2% vs 66.2—58.6%, respectively (p<0.05); signs of diastolic dysfunction also were more common in the comparison group (p<0.05).